Pharmaceutical M&A came back with a bang during October, after a quiet September. Merck & Co (NYSE: MRK) and AbbVie (NYSE: ...

Sanofi announced that it has entered into exclusive negotiations with the US private equity firm Clayton, Dubilier & Rice (CD&R) to transfer around 50% controlling stake in Opella.

US-based investment firm takes controlling stake in Opella, while France's government moves to ensure the company remains in ...

Jobs — and national identity — top French concerns over the news that pharmaceutical company Sanofi plans to sell 50% of ...

Located in midtown Manhattan and designed by SHoP Architects, the 1,428-foot-high skyscraper is the second tallest ...

The key to Sanofi becoming a pure biopharma player: investment. A year later, the French company announced the divestment of ...

Adults in their 30s are at risk of developing metabolic-associated fatty liver disease (MAFLD) due to metabolic changes in ...

You need to be a subscriber to view this content.

Any deal would follow Sanofi’s agreement to sell a controlling stake in its consumer health unit to Clayton Dubilier & Rice in a transaction valuing the Opella unit at about €16 billion. Bain and ...

The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Opella Healthcare Participations BV The Exchange has ...